ENSG00000291006 and ovarian carcinoma: A trend of low expression of LOC730101 was also detected in drug-resistant ovarian cancer cells, and ex vivo experiments also demonstrated that high expression of LOC730101 promoted ovarian cancer sensitivity to cisplatin and PARP inhibitors.